Analytical Challenges for Gene Therapy
03rd November 2020 | 10:00am EST | Clare Blue, Director of Analytical Development at Biogen |BOOK FREE SEAT FOR THIS WEBINAR
One of the biggest challenges for AAV gene therapy products is establishing an appropriate analytical strategy to support product manufacture, release, stability, comparability and characterization at different stages of development. This presentation will highlight some of the existing analytical challenges and provide guidance on development of an appropriate strategy to help overcome these.
Presented by Clare Blue, Director of Analytical Development at Biogen
Clare Blue holds a degree and PhD in Molecular Microbiology from the University of Glasgow, Scotland, UK. She has industry experience ranging from viral / vector manufacturing, biosafety testing, analytical development, QC and process development. Clare has been involved in AAV gene therapy for 6 years, initially at Nightstar Therapeutics where she held senior roles overseeing the manufacturing and analytical strategy of phase II/III AAV products for treating retinal diseases. In her current role as Director of Analytical Development, Biogen, she leads the analytical strategy for ophthalmology gene therapy products.